section name header

DRG Information

DRG Category: 713

Mean LOS: 4.0 days

Description: Surgical: Transurethral Prostatectomy With Complication or Comorbidity or Major Complication or Comorbidity


DRG Category: 725

Mean LOS: 5.3 days

Description: Medical: Benign Prostatic Hypertrophy With Major Complication or Comorbidity


Introduction

Benign prostatic hyperplasia (BPH; excessive proliferation of normal cells in normal organs) or hypertrophy (an increase in size of an organ) is one of the most common disorders of older men. It is a nonmalignant enlargement of the prostate gland and is the most common cause of obstruction of urine flow in men, resulting in more than 4.5 million visits to healthcare providers annually in the United States. The degree of enlargement determines whether or not bladder outflow obstruction occurs. As the urethra becomes obstructed, the muscle inside the bladder hypertrophies in an attempt to assist the bladder to force out the urine. BPH may also cause the formation of a bladder diverticulum that remains full of urine when the patient empties the bladder. With marked bladder distention, overflow incontinence may occur with any increase in intra-abdominal pressure, such as that which occurs with coughing and sneezing. Complications of BPH include urinary stasis, urinary tract infection, renal calculi, overflow incontinence, hypertrophy of the bladder muscle, acute renal failure, hydronephrosis, and even chronic renal failure.

Causes

Because the condition occurs in older men, changes in hormone balances have been associated with the cause. Androgens (testosterone) and estrogen appear to contribute to the hyperplastic changes that occur. Other theories, such as those involving diet, heredity, race, and history of chronic inflammation, have been associated with BPH, but no definitive links have been made with these potential contributing factors. Tobacco and alcohol use have been implicated in some studies.

Genetic Considerations

When BPH occurs in men under age 60 years and is severe enough to require surgery, chances of a genetic component are high. Autosomal dominant transmission appears likely because a man who has a male relative requiring treatment before age 60 years has a 50% lifetime risk of also requiring treatment. Recently, a variant in the gene RANBP3L was found to be associated with BPH risk.

Sex and Life Span Considerations

By the age of 60 years, 50% of men have some degree of prostate enlargement, which is considered part of the normal aging process. Many of these men do not manifest any clinical symptoms in the early stages of hypertrophic changes. As men become older, the incidence of symptoms increases to more than 75% for those over age 80 years and 90% by age 85 years. Of those men with symptoms, approximately 50% of men are symptomatic to a moderate degree, and 25% of those have severe symptoms that require surgical interventions.

Health Disparities and Sexual/Gender Minority Health

The prevalence of BPH is similar in White, Hispanic, and Black men, but symptoms of BPH tend to be more severe and progress more quickly in Black men as compared to other populations. One theory is that men with worse symptoms have higher testosterone levels and growth factor activity that lead to an increased rate of prostatic hyperplasia and gland enlargement. Most experts recognize that disparities in patient care for BPH exist for Black and Hispanic men because they receive lower levels of speciality care as compared to White men who are similarly insured.

Transgender is a term used to describe persons whose gender identity is different from their sex assigned at birth. Approximately 1% of the U.S. population identify themselves as transgender. Sexual and gender minority persons have higher odds for multiple chronic conditions, cancer, and poor quality of life and are more apt to have disabilities than cisgender males and females (cisgender is a term used to describe persons whose gender identity and gender expression are aligned with their assigned sex listed on their birth certificate). Gender-affirming hormone therapy is the use of hormone therapy for gender transition or gender affirmation and can be masculinizing or feminizing. Transgender women who take feminizing hormone therapy are not thought to increase the risk of prostate cancer or BPH (Cacerese, Jackman, et al., 2020; Gooren & T'Sjoen, 2018).

Global Health Considerations

BPH is a significant and widespread international problem that causes symptoms in at least 30 million men globally.

Assessment

ASSESSMENT

History

Generally, men with suspected BPH have a history of frequent urination, urinary urgency, nocturia, straining to urinate, weak stream, hesitancy, dribbling, and an incomplete emptying of the bladder. This group of symptoms is sometimes labeled LUTS, or lower urinary tract symptoms. Distinguish between these obstructive symptoms and irritative symptoms such as dysuria, frequency, and urgency, which may indicate an infection or inflammatory process. A “voiding diary” can also be obtained to determine the frequency and nature of the complaints. Elicit a sexual history because LUTS is an independent risk factor for erectile and ejaculatory dysfunctions. Some patients prefer having a male healthcare practitioner take a sexual history. The International Prostate Symptom Score (IPSS) has been adopted worldwide and provides information regarding symptoms and response to treatment (Box 1). Each question allows the patient to choose one of six answers on a scale of 0 to 5 indicating the increasing degree of symptoms; the total score ranges from 0 (mildly symptomatic) to 35 (severely symptomatic). The eighth question, known as the bother score, refers to quality of life.

Box 1 The International Prostate Symptom Score (International Prostate Symptom Score. [2021]. Urological Sciences Research Foundation. www.usrf.org/questionnaires/AUA_SymptomScore.html)

  1. Incomplete emptying: Over the past month, how often have you had the sensation of not emptying your bladder completely after you have finished urinating? (Not at all = 0, less than one time in five = 1, less than half the time = 2, about half the time = 3, more than half the time = 4, almost always = 5)
  2. Frequency: Over the past month, how often have you had to urinate again less than 2 hours after you finished urinating? (Not at all = 0, less than one time in five = 1, less than half the time = 2, about half the time = 3, more than half the time = 4, almost always = 5)
  3. Intermittency: Over the past month, how often have you stopped and started again several times when urinating? (Not at all = 0, less than one time in five = 1, less than half the time = 2, about half the time = 3, more than half the time = 4, almost always = 5)
  4. Urgency: Over the past month, how often have you found it difficult to postpone urination? (Not at all = 0, less than one time in five = 1, less than half the time = 2, about half the time = 3, more than half the time = 4, almost always = 5)
  5. Weak stream: Over the past month, how often have you had a weak urinary stream? (Not at all = 0, less than one time in five = 1, less than half the time = 2, about half the time = 3, more than half the time = 4, almost always = 5)
  6. Straining: Over the past month, how often have you had to push or strain to begin urination? (Never = 0, once = 1, twice = 2, three times = 3, four times or more = 4, five times or more = 5)
  7. Nocturia: Over the past month, how many times did you most typically get up to urinate from the time you went to bed until the time you got up in the morning? (Not at all = 0, less than one time in five = 1, less than half the time = 2, about half the time = 3, more than half the time = 4, almost always = 5)
  8. How would you feel if you were to spend the rest of your life with your urinary condition just the way it is now? (Delighted = 0, pleased = 1, mostly satisfied = 2, mixed = 3, mostly dissatisfied = 4, unhappy = 5, terrible = 6)

Physical Examination

Inspect and palpate the bladder for distention. A digital rectal examination (DRE) reveals a rubbery enlargement of the prostate, but the degree of enlargement does not consistently correlate with the degree of urinary obstruction. Some men have enlarged prostates that extend out into soft tissue without compressing the urethra. Determine the amount of pain and discomfort that is associated with the DRE.

Psychosocial

In addition to discomfort, the symptoms are anxiety producing to men. The patient who is experiencing BPH may voice concerns related to sexual functioning after treatment. The patient's degree of anxiety as well as his ability to cope with the potential alterations in sexual function (a possible cessation of intercourse for several weeks, possibility of sterility or retrograde ejaculation) should also be determined to provide appropriate follow-up care.

Diagnostic Highlights

TestNormal ResultAbnormality With ConditionExplanation
Urinalysis and cultureMinimal numbers of red and white blood cells; no bacteria; clear urine with no occult blood and no proteinUrinary tract infection may occur with the presence of bacteria, blood, leukocytes, protein, or glucoseUrinary retention may lead to infection; voiding may be irritating
UroflowmetryMales ages 4665 years have more than 200 mL of urine at a flow rate of 21 mL/secFlow rate is decreasedProstate inflammation leads to a narrowed urethral channel and obstruction of urine outflow
Prostate-specific antigen (PSA)Normal: < 4 ng/mLMay be slightly elevatedScreening for prostate cancer remains controversial and should be done if the physician and patient desire. PSA testing may reduce the likelihood of dying from prostate cancer. Patients should be alerted that PSA testing poses the risk of treatment of prostate cancer that would not have caused ill effects if left undetected.

Other Tests: Serum creatinine and blood urea nitrogen, electrolytes, postvoid residual volume, diagnostic ultrasound, cystourethroscopy, abdominal or renal ultrasound, transrenal ultrasound. Note that while BPH does not cause prostate cancer, men at risk for BPH are also at risk for prostate cancer. Screening for prostate cancer remains controversial (see diagnostic highlights above).

Primary Nursing Diagnosis

Diagnosis

DiagnosisImpaired urinary elimination related to urinary retention as evidenced by bladder distention, dribbling of urine, frequent voiding, and/or dysuria

Outcomes

OutcomesUrinary continence; Urinary elimination; Infection severity; Knowledge: Disease process, Medication, Treatment regimen; Symptom control

Interventions

InterventionsUrinary retention care; Bladder irrigation; Fluid management; Fluid monitoring; Medication administration; Infection control; Urinary catheterization; Urinary elimination management; Tube care: Urinary

Planning and Implementation

PLANNING AND IMPLEMENTATION

Collaborative

Medical.

Men with mild or moderate symptoms but without complications, and who are not bothered by their symptoms, may be monitored by “watchful waiting.” Generally these individuals will have an IPSS score of 8 or less. Most experts suggest that in this situation, the risks of medical treatment may outweigh the benefits, although most experts recommend annual examinations in case their condition changes.

Surgical.

Those patients with the most severe cases, in which there is total urinary obstruction, chronic urinary retention, and recurrent urinary tract infection, usually require surgery. Transurethral resection of the prostate (TURP) is the most common surgical intervention. The procedure is performed by inserting a resectoscope through the urethra. Hypertrophic tissue is cut away, thereby relieving pressure on the urethra. Prostatectomy can be performed, in which the portion of the prostate gland causing the obstruction is removed.

The relatively newer surgical procedure called transurethral incision of the prostate (TUIP) involves making an incision in the portion of the prostate attached to the bladder. The procedure is performed with local anesthesia and has a lower complication rate than TURP. The gland is split, reducing pressure on the urethra. TUIP is more helpful in men with smaller prostate glands that cause obstruction and for men who are unlikely to tolerate a TURP. Other minimally invasive treatments for BPH rely on heat to cause destruction of the prostate gland. The heat is delivered in a controlled fashion through a urinary catheter or a transrectal route, has the potential to reduce the complications associated with TURP, and has a lower anesthetic risk for the patient. Minimally invasive procedures include heat from laser energy, microwaves, radiofrequency energy, high-intensity ultrasound waves, and high-voltage electrical energy. Several minimally invasive therapies are continuously being tested and refined to increase efficacy and safety.

Postsurgical.

Postsurgical care involves supportive care and maintenance of the indwelling catheter to ensure patency and adequacy of irrigation. Belladonna and opium suppositories may relieve bladder spasms. Stool softeners are used to prevent straining during defecation after surgery. Ongoing monitoring of the drainage from the catheter determines the color, consistency, and amount of urine flow. The urine should be clear yellow or slightly pink in color. If the patient develops frank hematuria or an abrupt change in urinary output, the surgeon should be notified immediately. The most critical complications that can occur are septic or hemorrhagic shock.

Nonsurgical.

In patients who are not candidates for surgery, a permanent indwelling catheter may be inserted. If the catheter cannot be placed in the urethra because of obstruction, the patient may need a suprapubic cystostomy. Conservative therapy also includes prostatic massage, warm sitz baths, and a short-term fluid restriction to prevent bladder distention. Regular ejaculation may help decrease congestion of the prostate gland.

Pharmacologic Highlights

Medication or Drug ClassDosageDescriptionRationale
Phenoxybenzamine10 mg PO bidAlpha-adrenergic blockerBlocks effects of postganglionic synapses at the smooth muscle and exocrine glands; improvement of urinary flow in 75% of patients
Finasteride5 mg PO qd5-alpha reductase inhibitorShrinks prostate gland and improves urine flow

Other Drugs: Prazosin, alfuzosin, doxazosin, terazosin, silodosin, tamsulosin, dutasteride

Independent

Patients with severe alterations in urinary elimination may require a catheter to assist with emptying the bladder. Never force a urinary catheter into the urethra. If there is resistance during insertion, stop the catheterization procedure and notify the physician. Monitor the patient for bleeding and discomfort during insertion. In addition, assess the patient for signs of shock from postobstruction diuresis after catheter insertion. Ensure adequate fluid balance. Encourage the patient to drink at least 2 L of fluid per day to prevent stasis and infection from a decreased intake. Encourage the patient to avoid the following medications, which may worsen the symptoms: anticholinergics, decongestants (over-the-counter and prescribed), tranquilizers, alcohol, and antidepressants.

Evaluate the patient's and partner's feelings about the risk for sexual dysfunction. Retrograde ejaculation or sterility may occur after surgery. Explain alternative sexual practices and answer the patient's questions. Some patients would prefer to talk to a person of the same gender/sex when discussing sexual matters. Provide supportive care of the patient and significant others and make referrals for sexual counseling if appropriate.

Evidence-Based Practice and Health Policy

Srinivasan, A., & Wang, R. (2020). An update on minimally invasive surgery for benign prostatic hyperplasia: Techniques, risks, and efficacy. The World Journal of Men's Health, 38, 402411.

  • The authors reported on BPH, a common cause of lower urinary tract symptoms in older male adults. While previously BPH was conventionally treated by transurethral resection of the prostate, in recent years minimally invasive therapies (MITs) have become common because of their convenience, safety, and lack of side effects.
  • The authors review several novel types of MITs and note their mechanisms of action, contraindications, and advantages. These options personalize the approach to BHP and allow for patient choices depending on the patient's condition. Because there exists a dearth of data testing the long-term effects of these therapies, the authors suggest a series of clinical trials to determine best outcomes.

Documentation Guidelines

Discharge and Home Healthcare Guidelines

Patient Teaching.

Instruct patients about the need to maintain a high fluid intake (at least 2 L/day) to ensure adequate urine output. Teach the patient to monitor urinary output for 4 to 6 weeks after surgery to ensure adequacy in volume of elimination combined with a decrease in volume of retention. Explain that the patient should not do any heavy lifting or undergo strenuous exercise for several weeks after surgery.

Medications.

Provide instructions about all medications used to relax the smooth muscles of the bladder or to shrink the prostate gland. Provide instructions on the correct dosage, route, action, side effects, and potential drug interactions and when to provide this information to the physician.

Prevention.

Instruct the patient to report any difficulties with urination to the physician immediately. Explain that BPH can recur and that he should notify the physician if symptoms of urgency, frequency, difficulty initiating stream, retention, nocturia, or bladder distention recur. A diet low in fat and high in protein and vegetables may reduce the risk of the disorder. Regular alcohol consumption within recommended limits of drinking (no more than two standard drinks per day) is associated with a reduced risk of symptomatic BPH.

Postoperative.

Encourage the patient to discuss any sexual concerns he or his partner may have after surgery with the appropriate counselors. Reassure the patient that a session can be set up by the nurse or physician whenever one is indicated. Usually, physicians recommend that patients have no sexual intercourse or masturbation for several weeks after invasive procedures.